Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies, today acknowledged recent reports that the U.S. administration is preparing an executive order […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.